Company Description
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial.
The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers.
In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome.
Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
| Country | United States |
| Founded | 2017 |
| Industry | Real Estate Services |
| Sector | Real Estate |
| Employees | 23 |
| CEO | Howard Jonas |
Contact Details
Address: 520 Broad Street Newark, New Jersey 07102 United States | |
| Phone | 212 658 1450 |
| Website | rafaelholdings.com |
Stock Details
| Ticker Symbol | RFL |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Share Class | Class B Shares |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0001713863 |
| CUSIP Number | 75062E106 |
| ISIN Number | US75062E1064 |
| Employer ID | 82-2296593 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Howard S. Jonas | Chief Executive Officer, President, Founder and Executive Chairman |
| David A. Polinsky Esq. | Chief Financial Officer |
| Joshua M. Fine | Chief Operating Officer |
| Joyce J. Mason Esq. | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2025 | 8-K | Current Report |
| Nov 18, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 29, 2025 | 10-K | Annual Report |
| Oct 29, 2025 | 8-K | Current Report |
| Oct 28, 2025 | 8-K | Current Report |
| Oct 10, 2025 | 8-K | Current Report |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 18, 2025 | 8-K | Current Report |
| Jun 26, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 18, 2025 | 8-K | Current Report |